Licensing of GDNF for Parkinson’s Disease to Pfizer
PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease.
For press enquiries, please contact:
Senior Marketing Manager
+44 (0) 1865 332700
Oxford, UK. September 17th, 2014
PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson’s disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.
MedGenesis, a Canadian biotechnology company, has adapted the CED approach to enable unprecedented precision in delivery of drugs to predefined areas of the brain. Delivering GDNF to people with Parkinson’s disease in this way offers the possibility of treating the underlying disease rather than just the symptoms.
Adrian Dawkes, Vice President, who led the PharmaVentures team on the deal commented: “We are delighted to have worked with MedGenesis in partnering with one of the world’s leading pharmaceutical companies to complete development and commercialisation of the GDNF treatment. The CED technology could represent a paradigm shift in the treatment of Parkinson’s and many other neurological diseases”.
Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “PharmaVentures has a strong history in assisting companies in licensing but this agreement is quite special as it creates an exciting and unique partnership for the potential treatment of this debilitating disease “.